insitro and Bristol Myers Squibb Add New AI-Found Targets in ALS Research

The ongoing collaboration between insitro and Bristol Myers Squibb has been extended to include additional AI-discovered therapeutic targets for amyotrophic lateral sclerosis (ALS), with early experimental validation in human neuron models. The nomination of the two new targets triggered a $10 million milestone payment to insitro.